ARS Pharmaceuticals Q3 revenue rises on higher neffy sales

Overview

• Biopharmaceutical firm's Q3 revenue rose yr/yr, driven by higher U.S. neffy sales

• Company cut SG&A expenses 42% from prior year by reducing broad advertising

• Net loss narrowed from prior year as operating expenses declined

Outlook

• ARS reaffirms path to cash flow breakeven by end-2027

• Company expects 2H 2026 SG&A and R&D expenses of $114 mln to $126 mln

• ARS expects interim Phase 2b ARS-2 trial data in Q1 2027

Result Drivers

• TARGETED PROVIDER STRATEGY - Co said market share gains were concentrated in accounts targeted by its field team, reaching 9% in those accounts

• REDUCED ADVERTISING SPEND - SG&A expenses fell due to discontinuation of broad consumer advertising and shift to focused commercial investment

• ONE-TIME LICENSE PAYMENT - R&D expenses rose due to a $12.5 mln payment for exclusive rights to intellectual property

Company press release:

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy."

• Wall Street's median 12-month price target for ARS Pharmaceuticals, Inc. is $29.00, about 850.8% above its November 4 closing price of $3.05

Reuters Recommended Reads

• Nov 3 - Amgen Q3 revenue beats expectations on higher volumes

• Nov 2 - Vertex Pharmaceuticals' Q3 revenue slightly beats estimates, outlook raised

• Nov 3 - Pfizer Q3 revenue beats estimates on new launches; raises guidance

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)